[68ga]-nota-hgzp
mAbexperimentalImaging agent
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2019 (NCT04169321)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Granzyme BINHIBITOR
GZMB inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Imaging
- 68-Gallium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05285696 | Phase 1 | Sep 1, 2022 | Cytosite Biopharma Inc., University of Alabama, Birmingham |
| NCT04169321 | Phase 1 | Dec 1, 2019 | — |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cytosite Biopharma Inc. | For profit | 1 | 1 | 1 | 2022 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1